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Abstract
AIM
To evaluate the inflammatory state in Crohn’s disease 
(CD) patients and correlate it with genetic background 
and microbial spreading.
METHODS
By means of flow cytometry, production of tumor 
necrosis factor-alpha (TNF-α) was measured in 
peripheral blood monocytes from patients suffering 
from CD, ulcerative colitis (UC) and in healthy subjects 
after stimulation of the NOD2 and TLR pathways. CD 
patients were genotyped for the three most common 
NOD2 variants (R702W, G908R and L1007Pfs*2) and 
basal production of TNF-α was correlated to NOD2 
genotype. Also, production of TNF-α was correlated to 
plasmatic levels of LPS Binding Protein (LBP), soluble (s) 
CD14 and to the activity state of the disease.
RESULTS
The patients with CD were characterized by a signi-
ficantly higher monocyte basal expression of TNF-α 
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compared with healthy subjects and UC patients, and 
after stimulation with Pam3CSK4 (ligand of TLR2/1) 
and MDP-L18 (ligand of NOD2) this difference was 
maintained, while other microbial stimuli (LPS, ligand 
of TLR4 and PolyI:C, ligand of TLR3) induced massive 
activation in CD monocytes as well as in UC and 
in healthy control cells. There was no significant 
difference in the production of TNF-α between 
patients who carried CD-associated heterozygous or 
homozygous variants in NOD2  and patients with wild 
type NOD2 genotype. Although serum LBP levels have 
been shown to correlate positively with the state of 
activity of the disease, TNF-α production did not show 
a clear correlation with either LBP or sCD14 levels 
in plasma. Moreover, no clear correlation was seen 
between TNF-α production and activity indices in either 
CD or UC.
CONCLUSION
Peripheral monocytes from CD express higher basal 
and stimulated TNF-α than controls, regardless of 
NOD2  genotype and without a clear correlation with 
disease activity.
Key words: Crohn’s disease; Ulcerative colitis; Tumor 
necrosis factor-α; NOD2  variants; Toll like receptors; 
Dysbiosis; Activity index; LPS-binding protein
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Core tip: Crohn’s disease (CD) is characterized by an 
aberrant activation of the mucosal immune system 
in genetically susceptible subjects, who often harbor 
variants in genes involved in the innate immunity. 
To study the integrity of innate immune response, 
the activity of the TLR and NOD2 pathways was 
investigated, measuring TNF-α expression in peripheral 
blood monocytes. CD monocytes showed a higher 
production of TNF-α, which was not clearly related to 
disease activity, to NOD2 genotype or to the presence 
of translocated bacteria (indirectly measured by serum 
LPS-binding protein), indicating that this TNF-α hyper-
production may rely on a NOD2-independent pathway 
and is not due to systemic exposure to LPS.
Loganes C, Pin A, Naviglio S, Girardelli M, Bianco AM, 
Martelossi S, Tommasini A, Piscianz E. Altered pattern of 
tumor necrosis factor-alpha production in peripheral blood 
monocytes from Crohn’s disease. World J Gastroenterol 2016; 
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INTRODUCTION
Inflammatory bowel diseases (IBD) are complex 
inflammatory conditions that include different chronic 
and relapsing intestinal diseases, such as Crohn’s 
disease (CD) and ulcerative colitis (UC). Both genetic 
and environmental factors are thought to play a role in 
determining the disease phenotype[1,2].
On the one hand, CD and UC both involve intestinal 
mucosa and share some clinical symptoms, i.e., 
bloody diarrhoea, abdominal pain and weight loss. 
On the other hand, they present peculiar clinical 
and pathogenic features. Indeed, major differences 
between the two pathologies are found in the 
localization of lesions: while CD interests the small 
intestine (ileum) in particular, UC manifestations are 
localized mainly in the colon and rectum. Moreover, CD 
intestinal lesions, differently from UC, cause transmural 
inflammation and are characterized by skip lesions, 
alternating inflamed and not inflamed regions[3].
Diagnosis is based on clinical symptoms and 
medical history of the patients and then confirmed by 
endoscopic evaluations and histology. The classification 
of the disease, which is useful for prognosis and 
management of patients, is based on index of activity. 
In particular, the reference scores for pediatric patients 
is the Pediatric Crohn’s disease Activity Index (PCDAI)[4] 
and the Pediatric Ulcerative Colitis Activity Index 
(PUCAI)[5,6].
The immunopathogenesis underlying CD involves 
immune cells, such as monocytes, macrophages, 
neutrophils, recruited and activated via inflammatory 
cytokines, i.e., interleukin 6, interleukin 10, Interferon-
gamma and Tumor Necrosis Factor-alpha (TNF-α) 
as well as commensal microbiota[7]. In contrast, 
lymphocytic immune dysregulation seems to play an 
important role in UC, as shown by the increase of T 
cells activation markers and cytokines. Several gene 
variants are associated with the activity of the T cells 
and with the control of mucosal inflammation[8]. 
Although the etiopathology of CD is still unclear, 
several studies have linked the onset of the disease 
with an imbalance between mucosal immune system 
and microbiota[9,10]. For this reason, it has been 
suggested that CD inflammation may represent the 
compensatory response to a variety of minor defects 
in mucosal innate immunity. These deficiencies may 
account for changes in the intestinal microbiota 
(dysbiosis), which, together with multifactorial damages 
of the intestinal barrier, may facilitate bacterial 
translocation to the lamina propria and engagement 
of inflammatory cells. Microbial components from 
translocated bacteria can reach mesenteric lymph 
nodes and the bloodstream, making it possible to 
measure lipopolysaccharide (LPS), LPS-binding Protein 
(LBP) and soluble (s)CD14, as markers of bacterial 
spread across the intestinal mucosa[11]. Moreover, 
the circulating microbial components can induce 
excessive stimulation of toll like receptors (TLRs) 
followed by exacerbated activation of the immune 
system. It has been proposed that genetic variants 
in nucleotide oligomerization domain 2 (NOD2), the 
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first gene associated with IBD[12-14], may contribute 
to increasing the risk of disease by interfering with 
the response of monocytes to bacterial compounds. 
NOD2 is a cytoplasmic receptor that specifically 
recognizes muramyl dipeptide (MDP) present on the 
bacterial wall. It is involved in the regulation of acute 
inflammation, secreting pro-inflammatory cytokines 
such as TNF-α[15]. However, despite the huge amount 
of researches on this topic, it is still not clear how 
CD-associated NOD2 variants may contribute to 
the pathogenesis of the disease. On the one hand, 
dysfunctional pathogen associated molecular patterns 
(PAMPs) sensing in CD, involving NOD2 and other 
TLR pathways, could lead to altered shaping of gut 
microbial species, or dysbiosis[16-18]. On the other hand, 
NOD2 deficiency could lead to impaired autophagy 
and inflammation, with excessive response to TLR 
stimulation[19].
All this considered, a first aim of this study was to 
evaluate NOD2 and TLR signaling pathway integrity 
in CD. Immune activation was evaluated in terms of 
production of TNF-α by peripheral monocytes, since 
the NOD2 pathway is particularly important in these 
cells. Moreover peripheral blood monocytes are good 
representatives of the innate immune system and can 
easily be obtained from patients during blood sampling 
performed for clinical purposes. 
CD monocytes were activated with different purified 
microbial compounds [MDP-L18 (NOD2 ligand), LPS 
(TLR4 ligand), Pam3CSK4 (TLR2/1 ligand), Poly I:C (TLR3 
ligand)]. Production of TNF-α was then evaluated by 
flow cytometry in comparison with samples from UC 
and healthy donors. Intracellular production of TNF-α 
was correlated with the activity state of the disease, 
with the genotype of the patients and with the levels of 
plasmatic LBP and sCD14. 
As expected, CD patients displayed higher monocyte 
TNF-α production in basal condition and after stimulation 
of NOD2 and TLR2/1. Conversely, stimulation of 
TLR3 and TLR4 induced similar TNF-α production 
among CD, UC and healthy donors, suggesting that 
in CD, monocytes might be primed by mycobacterial 
components that can induce reduced tolerance to 
PAMPs. Neither the variants in NOD2 susceptibility gene 
nor the state of activity of the disease (PCDAI score) 
correlated with intracellular TNF-α. Moreover, the levels 
of plasmatic LPB, which have been shown to correlate 
positively with the activity of the disease, did not exhibit 
a clear correlation with monocyte activation. 
MATERIALS AND METHODS
Patient recruitment
Monocytes were obtained from heparinized blood of 38 
CD patients, 31 UC patients (diseased controls) and 50 
healthy donors (HD; negative controls) subsequent to 
receiving written consent. All subjects were recruited 
from the Gastroenterology and Clinical Nutrition Unit 
of the Institute for Maternal and Child Health IRCCS 
“Burlo Garofolo”, Trieste, Italy. The IBD patients were 
classified according to the disease activity evaluated 
by physician global assessment (based on PCDAI and 
PUCAI scores).
The present study was approved by the Institutional 
Review Board of the Institute for Maternal and Child 
Health “Burlo Garofolo” (RC 03/2009).
Intracellular cytokine staining
This cytometric technique allows for the detection 
of intracellular TNF-α in monocytes stimulated 
with synthetic microbial stimuli, to investigate the 
functionality of the innate immune pathway. The 
protocol was adapted from Takada et al[20].
Briefly, Peripheral Blood Mononuclear Cells (PBMCs) 
were isolated from whole heparinized blood by cen-
trifugation on Ficoll separating solution (Lympholite, 
Cederlane, Burlington, NC, United States) at 500 × 
g for 30 min at room temperature. 2 × 105 PBMCs 
were resuspended in 200 µL of culture medium (RPMI, 
EuroClone, Milano, Italy) supplemented with 10% 
human AB serum (Sigma Aldrich, Milano, Italy), 2 
mmol/L L-glutamine (EuroClone), 100 U/mL penicillin 
(EuroClone) and 0.1 mg/mL streptomycin (EuroClone) 
and stimulated with TLR and NOD2 ligands: 100 ng/ml 
Lipopolysaccharide (LPS; TLR4 ligand, Sigma Aldrich), 
10 µg/mL Polyinosinic-polycytidylic acid sodium salt 
(PolyI:C; TLR3 ligand, Sigma Aldrich), 500 ng/mL L-18 
Muramyl DiPeptide (MDP-L18; NOD2 ligand, InvivoGen, 
San Diego, CA, United States), 500 ng/mL Pam3CSK4 
(TLR2/1 ligand, InvivoGen) for an initial period of 30 
min at 37 ℃, in a CO2 incubator. Subsequently, 10 µg/
mL of Brefeldin A (BFA, Sigma Aldrich) were added to 
inhibit the secretion of newly synthesized cytokines and 
cells were incubated for additional 3.5 h. BFA, without 
any stimulus, was added to the unstimulated control 
tube. After incubation, FITC conjugated anti-CD14 
antibody (eBiosciences, San Diego, CA, United States) 
was added for surface staining to identify monocytes, 
followed by a fixation step with FACS Lysing Solution 
(BD Biosciences, San Jose, CA, United States). 
After centrifugation at 300 × g for 8 min, cells were 
permeabilized using FACS Permeabilizing Solution 2 (BD 
Biosciences). PBMCs were washed with Wash Buffer 
(PBS + 1% BSA + 0.1% NaN3), and anti-TNF-α PE 
antibody (BD Biosciences) was added to perform the 
intracellular staining. A fluorescent-conjugated isotype 
control antibody was used to detect non-specific 
bindings (PE IgG Isotype control, BD Biosciences). 
Finally, after an additional wash, the cells were fixed 
with PBS + 1% paraformaldehyde for analysis on a 
flow cytometer. Data were acquired on a CyAn ADP 
flow cytometer (Beckman Coulter, Fort Collins, CO, 
United States) and analyzed using FlowJo software v 
7.6 (TreeStar, Ashland, OR, United States). Results are 
expressed as percent of TNF-α positive monocytes, 
after gating on CD14 positive cells.
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Corporation, Madison, United States). The concentration 
of each sample was calculated from the standard curve, 
obtained by plotting absorbance vs known standard 
concentrations. 
Statistical analysis
All statistical analyses were performed using GraphPad 
Prism software version 5 (GraphPad, SanDiego, United 
States).
Data on intracellular TNF-α production are ex-
pressed as mean ± standard error of mean (SEM), 
while values of plasmatic proteins are described as 
medians and interquartile ranges and are represented 
with box plots using Tukey’s whiskers.
Statistical significance was assessed by one-way 
analysis of variance (ANOVA) with Kruskal-Wallis non-
parametric test and denoted by letters (aP < 0.05, bP < 
0.01, cP < 0.001). 
RESULTS
The clinical characteristics of all the patients included in 
the study are presented in Supplementary Table 1 and 
summarized in Table 1. 
Monocyte intracellular TNF-α  expression
To study the production of TNF-α by monocytes, cells 
were isolated from peripheral blood of patients with 
CD and UC and of healthy donors (HD). Monocytes 
were stimulated with TLR and NOD2 purified stimuli: 
LPS (TLR4 ligand), Pam3CSK4 (TLR2/1 ligand), Poly I:
C (TLR3 ligand) and MDP-L18 (NOD2 ligand). TNF-α 
expression in monocytes was analyzed by flow 
cytometry after gating on CD14 positive cells.
Both CD and UC showed increased basal expression 
of TNF-α (unstimulated) compared to healthy donors 
(HD 4.3 ± 0.4; CD 14.5 ± 2.5, P < 0.01; UC 10.7 ± 1.9, 
P < 0.05) (Figure 1A).
After stimulation with Pam3CSK4 (TLR2/1 ligand), a 
higher percentage of activated monocytes producing 
TNF-α was recorded in CD compared with HD (CD vs 
HD: 68.4 ± 2.7 vs 55.6 ± 2.1, P < 0.01) (Figure 1B), 
while stimulation with MDP-L18 (NOD2 ligand) induced 
a significant higher production of TNF-α in CD compared 
to both HD and UC (CD 44.2 ± 3.0; UC 30.2 ± 3.0, P < 
0.01; HD 24.9 ± 1.4, P < 0.001) (Figure 1C). 
Stimulation with LPS (TLR4 ligand) or Poly I:C (TLR3 
ligand) did not lead to significant differences among the 
three groups (respectively Figure 1D and Figure 1E).
TNF-α  expression and NOD2 genotype 
A genetic survey was carried out on 36 available 
patients with CD (out of 38). PCR and DNA sequencing 
analyses revealed that 13 patients were homozygous 
or heterozygous for one or more of the three CD-
associated genetic variants in NOD2 (Table 2). The 
remaining 23 patients were found to be wild type for 
the three polymorphisms (Supplementary Table 1).
NOD2 variant analysis 
CD patients were screened using targeted gene 
sequencing to identify the three principal variants 
in NOD2 susceptibility gene [c.2104C>T;p.R702W 
(rs2066844), c.2722G>C;p.G908R (rs2066845) and 
c.3016_3017insC; p.L1007Pfs*2 (rs2066847)]. 
DNA samples were collected from patients suffering 
from CD (n = 36). Genomic DNA of each patient was 
extracted from 1-2 ml EDTA-anticoagulated blood using 
the EZ1 DNA Blood Kit (QIAGEN, Valencia, CA, United 
States) according to the manufacturer’s instructions. 
To analyze the three IBD associated variants in the 
NOD2 gene (NM_022162), Polymerase chain reaction 
(PCR) amplification was performed using the KAPA 
2G Fast Hot Start Readymix (RESNOVA, Rome, Italy). 
Purified PCR products were directly sequenced in both 
directions using the amplification primers by the ABI 
PRISM 3130XL automated DNA Sequencer (Applied 
Biosystems, United States). Sequences were analyzed 
using Seqman II Software (DNASTAR I Lasergene 
7.0, Madison, WI, United States). Primers, used for 
PCR and sequencing were designed using Primer 
Blast, based on the relative sequence deposited in 
GeneBank. The specific primers for each variant are 
listed below: 
R702W_For 5’-CTTCAACCTTCTGCAGGGC-3’
R702W_Rev 5’- GGTGGCAGAGGCGAAGCT-3’
R702W_sequencing_For 5’-TGCTGATGTGCCACCAG-3’
G908R_For 5’-CTGCCCCTCTGGCTGGGACT-3’
G908R_Rev 5’-CCCAGCTCCTCCCTCTTC-3’
L1007Pfs*2_For 5’-GTAGACTGGCTAACTCCTGC-3’
L1007Pfs*2_Rev 5’-AGGAGGGCGGGAGCTGACTT-3 
LPS-Binding Protein and soluble CD14 quantification
Samples were collected from patients suffering 
from CD (n = 27), UC (n = 22) and from healthy 
individuals (n = 36). Plasma samples were obtained by 
centrifuging heparinized blood at 1300 × g for 10 min 
and were stored at -80 ℃ until LBP and sCD14 levels 
were measured.
Quantifications were performed using the LPS-
binding Protein (Human) ELISA kit (Abnova, Taipei 
City, Taiwan) and the human CD14 ELISA kit 
(RayBio, Norcross GA, United States), following the 
manufacturer’s instructions.
Absorptions were measured at 450 nm with a 
GloMax®-Multi+ Microplate Multimode Reader (Promega 
Table 1  Characteristics of Inflammatory bowel diseases patients 
included in the study
Patients Age (yr) Male/female Active/remission
(n  = 69) (mean ± SD)
CD (n = 38) 13 ± 4.47 25/13 18/20 
UC (n = 31) 13 ± 5.13 15/16 19/12 
CD: Crohn’s disease; UC: Ulcerative colitis.
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After grouping CD patients based on NOD2 geno-
type, no significant differences in TNF-α positive mono-
cytes were detected between patients with wild type 
or mutated genotype (CD WT: 14.87 ± 3.1 vs CD Mut 
13.82 ± 4.5) (Figure 2). Data regarding the single 
NOD2 variants are shown in Supplementary Figure 1. 
TNF-α  expression and disease activity index
Intracellular production of TNF-α by monocytes from 
CD and UC patients was correlated to the disease 
activity score, expressed as PCDAI (Pediatric Crohn’s 
Disease Activity Index) or PUCAI (Pediatric Ulcerative 
Colitis Activity Index). No correlation between the two 
parameters was found, either in CD (R2 = 0.004) or in 
UC (R2 = 0.01) subjects (Figure 3). 
TNF-α  expression and LBP and sCD14 levels
Plasmatic levels of LBP and sCD14 were measured to 
verify if the basal inflammatory state in CD patients 
could be due to exposition of monocytes to microbial 
components in peripheral blood. 
Levels of LBP were higher in plasma from patients with 
CD compared to HD [(median CD 19.11 (16.35-21.89), 
HD 15.01 (11.85-18.84), P < 0.05)] (Figure 4A) and this 
condition was noticed also when patients were grouped 
by disease activity [(median activeCD: 20.44 (16.81- 
26.31) vs HD: 15.01 (11.85-18.84); P < 0.05)] (Figure 
4B); furthermore a significant difference was also found 
Figure 1  Intracellular tumor necrosis factor-alpha expression in peripheral monocytes. Intracellular TNF-α expression in peripheral monocytes derived from 
patients affected by Crohn’s disease (CD), ulcerative colitis (UC) and healthy donors (HD), in basal condition (A), or after stimulation with Pam3CSK4 (B), MDP-L18 (C), 
LPS (D) or Poly I:C (E). Data are presented as mean ± SEM. Statistical significance is denoted by letters (aP < 0.05, bP < 0.01, cP < 0.001 vs HD). 
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between UC in active or remissive phase [(median UC: 
20.74 (14.55- 21.57) vs rUC: 12.35 (8.35-13.5); P < 
0.05)] (Figure 4B). 
LBP values displayed a significant correlation with 
the disease activity index, especially for CD (R2 = 0.40, 
P < 0.001) (Figure 4C and D). However, there was no 
correlation between monocyte TNF-α expression in 
basal condition and plasmatic levels of LBP in any of 
the analyzed groups (CD: R2 = 0.04, UC: R2 = 0.0004, 
HD: R2 = 0.005) (Figure 5).
The quantification of sCD14 was not significantly 
different among the three groups and did not correlate 
with the degree of monocyte activation in CD (data not 
shown).
DISCUSSION
The activation of the innate immune system is thought 
to play a pivotal role in the pathogenesis of CD. Most 
genetic variants associated with the disease involve 
genes that are expressed in monocytes and that 
contribute to functional innate response to microbes. 
For example, NOD2 and ATG16L1 are involved in 
the response to molecular patterns associated with 
pathogens (PAMPs) and in autophagy, a process 
that can amplify the inflammatory response to 
phagocytized materials. Notably, there is a number of 
genes and processes involved in phagocytic function 
and innate immunity that have been shown to be 
responsible for rare monogenic forms of Crohn’s-like 
intestinal inflammation. For instance, early onset CD-
like inflammatory bowel disease has been described 
in neutropenias and in functional deficiencies of 
phagocytes, such as chronic granulomatous disease 
and leukocyte adhesion deficiency, as well as in defects 
of other genes interacting with the NOD2 pathway of 
response to PAMPs, such as XIAP[8,21]. These findings 
have raised the question of whether CD should be 
considered more like an immunodeficiency than an 
autoinflammatory condition[22-24]. 
Figure 2  Intracellular tumor necrosis factor-alpha expression in wild 
type or mutation-carrier patients. Intracellular TNF-α expression in basal 
conditions measured in peripheral monocytes derived from patients affected by 
Crohn’s disease (CD), grouped into Wild Type (WT) or mutation carriers (Mut) 
for the three NOD2 polymorphisms (R702W, G908R and L1007Pfs*2). Data are 
presented as mean ± SEM. No statistical significances was found.
Figure 3  Correlation of disease activity index with monocyte expression 
of tumor necrosis factor-alpha in inflammatory bowel disease patients. 
Correlation of activity index, expressed by PCDAI (Pediatric Crohn’s disease 
Activity Index) or PUCAI (Pediatric Ulcerative Colitis Activity Index) with 
monocyte expression of TNF-α in patients suffering from Crohn’s disease (CD) 
and ulcerative colitis (UC). The squared Pearson correlation coefficients (R2) 
are shown.  
Table 2  NOD2 genotype analysis in Crohn’s disease patients 
CD patient NOD2 genotypes
Ex. 4 Ex. 8 Ex. 11
C>T G>C InsC
R702W G908R L1007Pfs*2
3 C/C G/G InsC/-
4 T/T G/G -/-
7 C/T G/G InsC/-
14 C/C G/C -/-
18 C/C G/C InsC/-
24 C/T G/G -/-
25 C/C G/C -/-
44 C/C G/G InsC/-
45 C/C G/G InsC/-
47 C/C G/C InsC/-
53 C/C G/G InsC/-
54 C/C G/C -/-
63 C/C G/G InsC/-
Details of the three NOD2 polymorphisms (R702W, G908R, L1007Pfs*2) 
that were found in heterozygous or in homozygous form in 13 of the CD 
patients. The 23 patients who were found to be wild type are not listed in 
the table.
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For this reason, several studies have investigated 
the function of peripheral blood monocytes, an easily 
available sample cell that can be, at least in part, 
representative of the innate immune profile of CD. 
The observation of impaired monocyte/macrophage 
function against yeast particles dates back decades[25]. 
However, it is still not clear whether these defects are 
a cause or a consequence of CD inflammation. For 
example, it has been hypothesized that CD-associated 
monocytes may display hyporesponsiveness because 
of massive mucosal stimulation[26]. Indeed, we and 
other groups have demonstrated that peripheral blood 
monocytes from CD show an increased expression 
of activation markers[27-29], whilst ex-vivo maturation 
of dendritic cells may be somehow impaired[30]. 
Overall, these results have highlighted the paradox 
of defective and excessive immunities in CD[31]: CD 
monocytes display increased activation and production 
of inflammatory cytokines, but they may present 
functional defects in terms of capacity to mature 
effectively and to clear bacteria efficiently[32]. Indeed, 
the depletion of monocytes could improve the response 
to anti-inflammatory treatments in CD[33]. Thus, the 
contribution of monocytes to the pathogenesis of CD 
seems to be quite complex, involving hyper-activation 
and defective functionality at the same time. 
Beynon et al[34] demonstrated that in spite of 
increased basal activation, CD-associated monocytes 
display reduced response to MDP stimulation, in a 
manner that greatly depends on NOD2 genotype. The 
effect of NOD2 variants on the activation of monocytes 
has been confirmed by other studies showing that 
homozygous mutations can almost abrogate TNF-α 
production after MDP stimulation[35]. However, NOD2 
defects can also impair MDP-induced tolerance, 
resulting in sustained monocyte activation and TNF-α 
production[36]. 
The aim of our research was the analysis of the 
integrity of the different pathways of the innate immune 
network. By means of a cytometric protocol, adapted 
from a clinically oriented technique already used for 
the screening of some primary immunodeficiency[20], 
we analysed the production of TNF-α triggered in 
monocytes by different stimuli, to depict possible 
alterations in different pathways of innate immunity to 
PAMPs. 
We demonstrated that peripheral monocytes from 
CD show significant basal production of TNF-α and that 
this is not clearly related to either the disease activity 
or the NOD2 genotype, supporting the idea that, 
in these cases, hyper-production of TNF-α relies on 
NOD2-independent pathways. Indeed, stimulation with 
Figure 4  Dosage of LPS-binding protein and correlation with disease activity index. A, B: Quantification of plasmatic LPS-Binding Protein (LBP) from patients 
affected by active Crohn’s disease (CD), remissive Crohn’s disease (rCD), active Ulcerative Colitis (UC), remissive Ulcerative Colitis (rUC) and healthy donors (HD). 
Data are represented with box plots using Tukey’s whiskers. Statistical significance is denoted by letters (aP < 0.05); C, D: Correlation between activity Index, expressed 
by PCDAI (Pediatric Crohn’s Disease Activity Index) or PUCAI (Pediatric Ulcerative Colitis Activity Index) with plasmatic level of LBP in patients with Crohn’s disease (CD) 
(C, R2 = 0.40) or Ulcerative Colitis (UC) (D, R2 = 0.25). The squared Pearson correlation coefficients (R2) and the P value are shown.  
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MDP or with Pam3CSK4 led to higher TNF-α production 
in CD patients than in controls. The stronger response 
in CD after the stimulation with the NOD2 ligand 
did not find a clear explanation, but it highlights the 
importance of NOD2 signalling in CD and not in UC. 
This result is coherent with the knowledge that NOD2 
is the main genetic factor associated with CD, even 
though the mechanisms underlying the pathogenesis 
of the disease remain controversial. 
Thus, the activation of monocytes resulting from 
the mucosal immunopathology of CD could play 
a greater role in inducing TNF-α than the NOD2 
genotype, not only in the intestinal mucosa but also 
in peripheral blood. A possible hypothesis is that 
excessive activation of monocytes occurs in response 
to bacterial translocation across the epithelium and to 
minor defects in bacterial clearance or in MDP-induced 
tolerance. Notably, the paradoxical efficacy of GM-
CSF in some cases of CD may be due to the correction 
of such defects in epithelial monocytes, for example 
by rescuing their epithelial repair function[37]. Another 
critical function for mucosal monocytes may concern 
the induction of antimicrobial peptide production 
by Paneth cells[38]; indeed, a defective production 
of defensins after bacterial translocation may result 
in altered shaping of gut microbiota, leading to 
inflammatory amplification in a vicious circle. 
We investigated whether increased activation of 
peripheral monocytes correlated with plasma levels 
of LPS-binding protein (LBP). We showed that plasma 
concentrations of LBP correlate positively with disease 
activity, both in CD and in UC, in agreement with 
previous studies[11]. However, there was no significant 
correlation between LBP levels and activation of 
peripheral monocytes, suggesting that monocytes are 
not activated by systemic exposure to LPS. We cannot, 
however, rule out the existence of other bacterial 
molecular patterns. 
An added value of our research is that we studied 
monocyte function after stimulation of different TLR 
pathways. Several studies have already reported 
that altered patterns of TLR expression can be dif-
ferentially found in CD, rather than in UC[39], even 
though no definitive association between the pathway 
dysregulations and the disease phenotypes has been 
ever identified. We interestingly found that peripheral 
blood monocytes from CD patients displayed increased 
response to Pam3CSK4, which is a mycobacterial-
like ligand for TLR2/1. The increased response to 
Pam3CSK4 was quite specific to CD monocytes and 
was not found in UC. Thus, it is unlikely that the 
hyper-response to TLR2/1 signaling depended on 
monocyte activation alone. A possible explanation 
is that peripheral monocytes from patients with CD 
are primed by mycobacterial components released 
in the intestinal mucosa, maybe as a result of 
colonization with bacteria such as mycobacterium 
avium paratuberculosis (MAP). The presence of MAP 
in CD intestinal mucosa and bloodstream has been 
proved by several works and accomplished by different 
techniques; it has been repetitively associated with 
the pathogenesis of CD but its role in the etiology 
remains to be defined[40]. Our results should prompt 
further investigation on the immune response to MAP 
in healthy population and in CD.  
In conclusion, we showed that peripheral mono-
cytes from patients with CD have higher basal 
Figure 5  Correlation of monocyte tumor necrosis factor-alpha expression 
and LPS-binding protein levels in inflammatory bowel disease patients. 
Correlation between monocyte expression of tumor necrosis factor-alpha 
(TNF-α) and plasmatic level of LBP in patients affected by Crohn’s disease (CD) 
or ulcerative colitis (UC) and in healthy subjects (HD). The squared Pearson 
correlation coefficients (R2) are shown. No statistical significances were found.
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production of TNF-α than controls, regardless of NOD2 
genotype and without a clear correlation with disease 
activity. Moreover, peripheral monocyte activation does 
not seem to be due to plasma exposition to LPS. There 
is also an increased response of monocytes to MDP or 
Pam3CSK4 stimulation, which could reflect a reduced 
tolerance to bacterial PAMPs. Based on these data, it is 
worth investigating the possible priming of monocytes 
by mycobacterial colonization, for example with MAP. 
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